Search results
Results from the WOW.Com Content Network
Antistasin, the first discovered naturally occurring direct Xa inhibitor Rivaroxaban, the first synthetic direct Xa inhibitor marketed as a drug Prior to the introduction of direct factor Xa inhibitors, vitamin K antagonists such as warfarin were the only oral anticoagulants for over 60 years, and together with heparin have been the main blood ...
Andexanet alfa, sold under the brand name Andexxa among others, is an antidote for the medications rivaroxaban and apixaban, when reversal of anticoagulation is needed due to uncontrolled bleeding. [8] It has not been found to be useful for other factor Xa inhibitors. [9] It is given by injection into a vein. [9]
Apart from using unfractionated heparin instead, it may be possible to reduce the dose and/or monitor the anti-Xa activity to guide treatment. [3] The most common side effects include bleeding, which could be severe or even fatal, allergic reactions, injection site reactions, and increases in liver enzyme tests, usually without symptoms. [13]
Xarelto is a brand name for the drug rivaroxaban. Parts of Medicare cover the cost of prescription medication, including Part A, Part D, and Advantage plans.
Rivaroxaban, sold under the brand name Xarelto among others, is an anticoagulant medication (blood thinner) used to treat and prevent blood clots. [8] Specifically it is used to treat deep vein thrombosis and pulmonary emboli and prevent blood clots in atrial fibrillation and following hip or knee surgery. [ 8 ]
I (User:MattKingston) am in the process of creating a list of drugs and their various names. The list will be alphabetical and will use the following format (subject to change if better suggestions are put forward). All items in the list will follow the general format: Name of drug (who calls it that) [country]. Redirects to name of drug.
A new drug application (NDA) for the approval of apixaban was submitted to the US Food and Drug Administration (FDA) by Bristol-Myers Squibb (BMS) and Pfizer jointly after the conclusion of the ARISTOTLE clinical trial in 2011. [28] [14] Apixaban was approved for the prevention of stroke in people with atrial fibrillation in December 2012.
Two hydrogen bonds are formed and serve an important role directing rivaroxaban into the S1 and S4 subsites. Due to these hydrogen bonds, rivaroxaban forms a L-shape and fits in the pockets. Chlorine substituent of the drug interacts with Tyr-228 in the S1 pocket which enables rivaroxaban to achieve good oral bioavailability and potency.